Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.

Abstract Serum levels of TAG 72 were measured in 726 serum samples from patients with benign and malignant gynaecological conditions in order to evaluate the clinical usefulness of TAG 72 alone or in combination with other tumour markers. Sixty-six per cent of patients with ovarian cancer showed abnormal concentrations of TAG 72 antigen. A good correlation was also found between serial TAG 72 values and the clinical course of disease during chemotherapy and follow-up. In cervical and endometrial cancer abnormal TAG 72 values occurred in 23% and 14% of cases, while none of the patients with breast cancer had abnormal TAG 72 levels. Among patients with benign disease only one out of 12 patients (8%) with benign ovarian tumours and one of 15 patients with uterine fibromyomatosis (7%) showed high TAG 72 serum levels. However, the determination of TAG 72 did not increase the sensitivity of CA 125 and squamous cell carcinoma antigen (SCC), in ovarian and cervical cancer, respectively. The systemic administration of recombinant interferon alpha-2b to 15 patients with ovarian cancer and different basal levels of TAG 72 did not increase serum levels of the antigen. Full text PDFSelected References These references are in PubMed. This may not be the complete list of references from this article. - Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar] - Benedetti Panici P., Scambia G., Baiocchi G., Iacobelli S., Mancuso S. Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer. Gynecol Oncol. 1989 Dec;35(3):286–289. doi: 10.1016/0090-8258(89)90064-4. [DOI] [PubMed] [Google Scholar] - Berek J. S., Knapp R. C., Malkasian G. D., Lavin P. T., Whitney C., Niloff J. M., Bast R. C., Jr CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol. 1986 May;67(5):685–689. doi: 10.1097/00006250-198605000-00016. [DOI] [PubMed] [Google Scholar] - Boyer C. M., Dawson D. V., Neal S. E., Winchell L. F., Leslie D. S., Ring D., Bast R. C., Jr Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res. 1989 Jun 1;49(11):2928–2934. [PubMed] [Google Scholar] - Colcher D., Hand P. H., Nuti M., Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A. 1981 May;78(5):3199–3203. doi: 10.1073/pnas.78.5.3199. [DOI] [PMC free article] [PubMed] [Google Scholar] - Colcher D., Keenan A. M., Larson S. M., Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res. 1984 Dec;44(12 Pt 1):5744–5751. [PubMed] [Google Scholar] - Greiner J. W., Fisher P. B., Pestka S., Schlom J. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res. 1986 Oct;46(10):4984–4990. [PubMed] [Google Scholar] - Greiner J. W., Guadagni F., Noguchi P., Pestka S., Colcher D., Fisher P. B., Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987 Feb 20;235(4791):895–898. doi: 10.1126/science.3580039. [DOI] [PubMed] [Google Scholar] - Iacobelli S., Scambia G., Natoli C., Panici P. B., Baiocchi G., Perrone L., Mancuso S. Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells. Int J Cancer. 1988 Aug 15;42(2):182–184. doi: 10.1002/ijc.2910420207. [DOI] [PubMed] [Google Scholar] - Johnson V. G., Schlom J., Paterson A. J., Bennett J., Magnani J. L., Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986 Feb;46(2):850–857. [PubMed] [Google Scholar] - Kato H., Tamai K., Morioka H., Nagai M., Nagaya T., Torigoe T. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer. 1984 Oct 15;54(8):1544–1546. doi: 10.1002/1097-0142(19841015)54:83.0.co;2-b. [DOI] [PubMed] [Google Scholar] - Kato H., Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977 Oct;40(4):1621–1628. doi: 10.1002/1097-0142(197710)40:43.0.co;2-i. [DOI] [PubMed] [Google Scholar] - Klug T. L., Sattler M. A., Colcher D., Schlom J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer. 1986 Nov 15;38(5):661–669. doi: 10.1002/ijc.2910380508. [DOI] [PubMed] [Google Scholar] - Maruo T., Shibata K., Kimura A., Hoshina M., Mochizuki M. Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization. Cancer. 1985 Jul 15;56(2):302–308. doi: 10.1002/1097-0142(19850715)56:23.0.co;2-t. [DOI] [PubMed] [Google Scholar] - Niloff J. M., Bast R. C., Jr, Schaetzl E. M., Knapp R. C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol. 1985 Apr 1;151(7):981–986. doi: 10.1016/0002-9378(85)90678-7. [DOI] [PubMed] [Google Scholar] - Scambia G., Panici P. B., Baiocchi G., Perrone L., Iacobelli S., Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res. 1988 Jul-Aug;8(4):761–764. [PubMed] [Google Scholar] - Scambia G., Panici P. B., Iacobelli S., Baiocchi G., Battaglia F., Perrone L., Sonsini C., Ferrandina G., Natoli C., Mancuso S. Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer. 1990 Mar 15;65(6):1325–1328. doi: 10.1002/1097-0142(19900315)65:63.0.co;2-j. [DOI] [PubMed] [Google Scholar] - Schilthuis M. S., Aalders J. G., Bouma J., Kooi H., Fleuren G. J., Willemse P. H., De Bruijn H. W. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol. 1987 Mar;94(3):202–207. doi: 10.1111/j.1471-0528.1987.tb02354.x. [DOI] [PubMed] [Google Scholar] - Senekjian E. K., Young J. M., Weiser P. A., Spencer C. E., Magic S. E., Herbst A. L. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol. 1987 Aug;157(2):433–439. doi: 10.1016/s0002-9378(87)80187-4. [DOI] [PubMed] [Google Scholar] - Stramignoni D., Bowen R., Atkinson B. F., Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer. 1983 May 15;31(5):543–552. doi: 10.1002/ijc.2910310504. [DOI] [PubMed] [Google Scholar] - Thor A., Gorstein F., Ohuchi N., Szpak C. A., Johnston W. W., Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst. 1986 Jun;76(6):995–1006. [PubMed] [Google Scholar] - Thor A., Ohuchi N., Szpak C. A., Johnston W. W., Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986 Jun;46(6):3118–3124. [PubMed] [Google Scholar]